Clostridioides difficile Associated Enteropathy (Clostridium difficile Associated Enteropathy) – Pipeline Review, H2 2020

Global Markets Direct’s, ‘Clostridioides difficile Associated Enteropathy (Clostridium difficile Associated Enteropathy) – Pipeline Review, H2 2020’, provides an overview of the Clostridioides difficile Associated Enteropathy (Clostridium difficile Associated Enteropathy) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Clostridioides difficile Associated Enteropathy (Clostridium difficile Associated Enteropathy), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Clostridioides difficile Associated Enteropathy (Clostridium difficile Associated Enteropathy) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Clostridioides difficile Associated Enteropathy (Clostridium difficile Associated Enteropathy)

– The report reviews pipeline therapeutics for Clostridioides difficile Associated Enteropathy (Clostridium difficile Associated Enteropathy) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Clostridioides difficile Associated Enteropathy (Clostridium difficile Associated Enteropathy) therapeutics and enlists all their major and minor projects

– The report assesses Clostridioides difficile Associated Enteropathy (Clostridium difficile Associated Enteropathy) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Clostridioides difficile Associated Enteropathy (Clostridium difficile Associated Enteropathy)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Clostridioides difficile Associated Enteropathy (Clostridium difficile Associated Enteropathy)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Clostridioides difficile Associated Enteropathy (Clostridium difficile Associated Enteropathy) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Absynth Biologics Ltd

Acurx Pharmaceuticals LLC

Appili Therapeutics Inc

Artugen Therapeutics Ltd

Aviex Technologies LLC

AzurRx BioPharma Inc

Biomica

Botanix Pharmaceuticals Ltd

Boulos and Cooper Pharmaceuticals Pty Ltd

Cambimune Ltd

Chain Biotechnology Ltd

Crestone Inc

CSA Biotechnologies LLC

Daiichi Sankyo Co Ltd

Deinove SAS

Enterobiotix Ltd

Facile Therapeutics Inc

Finch Therapeutics Group

FloraSeq LLC

Fzata Inc

Galenus Therapeutics Inc

Gateway Pharmaceutical LLC

GlaxoSmithKline Plc

Immune Biosolutions Inc

ImmuneBiotech AB

ImmuniMed Inc

ImmunoBiology Ltd

Immuron Ltd

Inositec AG

Inovio Pharmaceuticals Inc

Inspyr Therapeutics Inc

Integrated BioTherapeutics Inc

Kaleido Biosciences Inc

KamTek Inc

KoBioLabs Inc

Locus Biosciences Inc

Lumen Bioscience Inc

Mapp Biopharmaceutical Inc

Matrivax Research & Development Corp

Merck & Co Inc

MGB Biopharma Ltd

Microbiotica Ltd

Micropharm Ltd

MV BioTherapeutics SA

MyBiotics Pharma Ltd

Novabiotics Ltd

NovoBiotic Pharmaceuticals LLC

Nubiyota LLC

Oragenics Inc

Ostrich Pharma USA Inc

PanTheryx Inc

Pfizer Inc

Procarta Biosystems Ltd

Proxi Biotech IVS

Pylum Biosciences Inc

Q2 Pharma Ltd

QureTech Bio AB

Rebiotix Inc

Recursion Pharmaceuticals Inc

Rise Therapeutics LLC

Scioto Biosciences Inc

Seres Therapeutics Inc

Serometrix LLC

Servatus Ltd

Summit Therapeutics Plc

Symbiotic Health Inc

Synterica Inc

Synthetic Biologics Inc

Takeda Pharmaceutical Co Ltd

The Broad Institute Inc

Valevia UK Ltd

Valneva SE

Vedanta Biosciences Inc

Vitality Biopharma Inc

XBiotech Inc

Xgene Pharmaceutical Inc

Zhiyi Pharmaceuticals Inc

Table of Contents

Table of Contents

Introduction

Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Overview

Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Therapeutics Development

Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Therapeutics Assessment

Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Companies Involved in Therapeutics Development

Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Drug Profiles

Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects

Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Discontinued Products

Clostridioides difficile Infections (Clostridium difficile Associated Disease) - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Clostridioides difficile Infections (Clostridium difficile Associated Disease), H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Products under Development by Companies, H2 2020

Products under Development by Universities/Institutes, H2 2020

Number of Products by Stage and Target, H2 2020

Number of Products by Stage and Mechanism of Action, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Absynth Biologics Ltd, H2 2020

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Acurx Pharmaceuticals LLC, H2 2020

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Appili Therapeutics Inc, H2 2020

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Artugen Therapeutics Ltd, H2 2020

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Aviex Technologies LLC, H2 2020

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by AzurRx BioPharma Inc, H2 2020

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Biomica, H2 2020

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Botanix Pharmaceuticals Ltd, H2 2020

Clostridioides difficile Infections (Clostridium difficile Associated Disease) – Pipeline by Boulos and Cooper Pharmaceuticals Pty Ltd, H2 2020

List of Figures

List of Figures

Number of Products under Development for Clostridioides difficile Infections (Clostridium difficile Associated Disease), H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Number of Products by Top 10 Targets, H2 2020

Number of Products by Stage and Top 10 Targets, H2 2020

Number of Products by Top 10 Mechanism of Actions, H2 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020

Number of Products by Routes of Administration, H2 2020

Number of Products by Stage and Top 10 Routes of Administration, H2 2020

Number of Products by Top 10 Molecule Types, H2 2020

Number of Products by Stage and Top 10 Molecule Types, H2 2020

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports